Suppliers / Henan Dongtai Pharm

Henan Dongtai Pharm

China Updated 9 July 2026

Henan Dongtai Pharm is an API manufacturer based in China. It holds 4 active US drug master files across a filed portfolio of 3 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 11 August 2023 as NAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 11 August 2023 NAI US FDA
  • 27 July 2018 VAI US FDA
  • 25 September 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3008294021

What they file, and where

Molecule Regulators Docs
Diclofenac US FDA 2
Allopurinol US FDA 1
Celecoxib US FDA 1

Also appears on these molecule pages

Allopurinol API Celecoxib API Diclofenac API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 3 None
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Henan Dongtai Pharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 11 August 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates